Nantahala Capital Management »

An2 Therapeutics shares owned by Nantahala Capital Management

Quarter-by-quarter ownership of An2 Therapeutics (ANTX) shares owned by Nantahala Capital Management from 13F filings

Historical chart of Nantahala Capital Management investment in An2 Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including An2 Therapeutics held by Nantahala Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in An2 Therapeutics by Nantahala Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $319k 98k 3.25
2023-12-31 $5.1M 248k 20.49
2023-09-30 $5.7M 357k 16.08

More positions owned by Nantahala Capital Management

Ishares Tr Russell 2000 Etf Put Option (IWM)
Spdr Ser Tr S&p Biotech (XBI)
Establishment Labs Holdings Ord (ESTA)
Soleno Therapeutics (SLNO)
Eli Lilly & Co. Put Option (LLY)
Grand Canyon Education Put Option (LOPE)
Meta Financial (CASH)
Costco Wholesale Corporation Put Option (COST)
Evolus (EOLS)
Peloton Interactive Cl A Com (PTON)
Imax Corp Cad (IMAX)
Hilton Grand Vacations (HGV)
Bioventus Com Cl A (BVS)
Rumbleon Com Cl B (RMBL)
Ishares Tr U.s. Real Es Etf Put Option (IYR)

View all positions for Nantahala Capital Management

Top funds holding An2 Therapeutics

RA Capital Management
Citadel Advisors
Frazier Life Sciences Management
BVF
Henderson Group
Avidity Partners Management
Octagon Capital Advisors
Vanguard Group
Adage Capital Partners GP
BlackRock
Susquehanna International
Geode Capital Management
Acadian Asset Management
Walleye Trading Advisors
Alyeska Investment Group

View all funds holding An2 Therapeutics